283173‑50‑2, Rucaparib: The Latest News | ANQING CHICO PHARMACEUTICAL CO., LTD.
AbstractRucaparib (Rubraca®) is an oral PARP‑1/2 inhibitor, initially developed through Newcastle University/Agouron by Clovis Oncology, and now commercialized by Pharma&. First approved in December 2016 by the FDA for BRCA‑mutated advanced ovarian cancer, its label expanded in April 2018 to maintenance therapy, and in May 2020 to include BRCA‑mutated metastatic castration‑resistant prostate cancer (mCRPC). It recently gained first-line ovarian cancer maintenance approval in the EU/UK in late 2023/early 2024. Global sales grew from an estimated USD 350 million in 2020 to USD 550 million in 2023, with projected 2024 revenues around USD 620 million. As part of the expanding PARP inhibitor market, rucaparib faces competition from olaparib, niraparib, talazoparib, and growing generic API demand. Ongoing pipeline expansion and label extensions underpin future growth.
Rucaparib; Rubraca; PARP inhibitor; ovarian cancer; prostate cancer; global sales; market competition; generics; Pharma&; ATHENA‑MONO
Rucaparib inhibits PARP enzymes involved in cancer cell DNA repair, particularly effective in BRCA‑mutated and platinum‑sensitive ovarian cancers, as well as mCRPC with BRCA alterations
CAS: 283173‑50‑2
Formula: C₁₉H₁₈FN₃O
Molecular Weight: 323.36
Appearance: Yellow solid
Melting Point: 187–189 °C; Boiling Point: ~625 °C
Density: ~1.281 g/cm³
Solubility: Slight in DMSO/methanol; pKa ~14.1
Rucaparib originated from Newcastle University/Agouron and was developed by Clovis Oncology. Clovis later divested it to Pharma& amid bankruptcy in 2023 . Key phase III trials include ARIEL3/4 and ATHENA-MONO supporting first-line label expansion.
Dec 19, 2016 (FDA): Accelerated approval for BRCA‑mutated advanced ovarian cancer .
Apr 6, 2018 (FDA): Approved for maintenance therapy in recurrent platinum-sensitive ovarian cancer .
May 15, 2020 (FDA): Accelerated approval for BRCA-mutated mCRPC.
Nov 20, 2023 (EC) & Jan 2024 (UK MHRA): First-line maintenance in advanced ovarian cancer regardless of BRCA status (ATHENA-MONO) .
| Year | Global Sales |
|---|---|
| 2020 | 350 |
| 2021 | 430 |
| 2022 | 500 |
| 2023 | 550 |
| 2024 | 620 (projected) |
Strong uptake post-label expansion; 2023 global annual sales reached approximately USD 550 M.
2024 projected growth (~12%) due to first-line approval in major markets (verifiedmarketreports.com).
The global Finished API market is expanding; North America and Europe lead in demand.
China/APAC markets show fast growth; API forecasted to reach ~USD 350 M by 2033.
Competing PARP inhibitors: olaparib, niraparib, talazoparib.
Rucaparib offers broad indication across ovarian and prostate cancers.
Patent expiry around 2028–2029 may trigger generic competition for API/tablets.
ATHENA-MONO trial triggered EU/UK first-line approvals .
Clovis Oncology’s bankruptcy led to the licensing out of Rubraca to Pharma& .
Combination with new agents, expansion into non-oncology DNA repair vulnerabilities anticipated.
PARP inhibitor market forecast to reach ~USD 6.3 B in 2024 with 8.7% CAGR to 2034.
Rucaparib poised for continued growth with expanded labels.
Generic competition post-patent expiry may affect pricing, especially in generics-ready markets.
Chemical properties & mechanism (de.wikipedia.org)
FDA approvals & trial data
Sales & API market data (fda.gov)
Regulatory expansion news
Commercial transition news
Active Pharmaceutical Ingredient
283173-50-2,Rucaparib,(chemical grade, purity ≥99.0%) are currently supplied by our company. [Own compliance factory, fully support factory audit] For details, you can call the bottom line to get the latest price of the product!
Disclaimer:Products are only available to countries where there is no valid patent protection. Products still covered by patents rights are available exclusively for experimental or registration purpose pursuant to national applicable law, and shall be sold in strict accordance with the laws of the People's Republic of China and the laws of the Buyer's country. All products are not for human use. Buyer is obligated for evaluation of the patent situation in its domestic market and shall be held liable for uses which do not fall within the scope of the experimental or registration use exception and are not permitted by national applicable law.
References or other information:
FDA,Wikipedia,Chatgpt,DeepSeek,chemicalbook,lookchem.
If there is any infringement, please apologize and delete. If there are any errors, welcome to criticize and correct.
Under no circumstances shall the information or opinions expressed herein be construed as investment advice for any person.
